Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Liabilities and Shareholders Equity (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $913.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity changed 0.3% to $913.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 billion, a 107.4% increase, with the full-year FY2025 number at $913.2 million, changed 0.3% from a year prior.
  • Liabilities and Shareholders Equity was $913.2 million for Q4 2025 at Iovance Biotherapeutics, up from $904.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $966.7 million in Q1 2025 to a low of $757.3 million in Q2 2023.
  • A 3-year average of $868.7 million and a median of $887.4 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 16.67% in 2024, then grew 0.3% in 2025.
  • Iovance Biotherapeutics' Liabilities and Shareholders Equity stood at $780.4 million in 2023, then increased by 16.67% to $910.4 million in 2024, then grew by 0.3% to $913.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Liabilities and Shareholders Equity are $913.2 million (Q4 2025), $904.9 million (Q3 2025), and $907.4 million (Q2 2025).